EUCTR2014-004972-49-DE进行中（未招募）1 期
A randomized, open label, controlled, multiple dose studyto evaluate the clinical efficacy, safety, tolerability,pharmacokinetics and pharmacodynamics of LFG316 inpatients with transplant associated microangiopathy afterhematopoietic precursor cell transplantation - CLFG316X2202
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Written informed consent/assent before any study-specific screening procedures.
- •For pediatric patients, consent will be obtained from parent(s) or legal guardian(s) and the
- •signature of at least 1 parent or guardian will be required. Investigators will also obtain
- •assent of patients according to local, regional or national guidelines.
- •2. Patients after allogeneic stem cell transplantation from a related or unrelated, HLAmatched
- •or mismatched donor with the diagnosis of transplant related microangiopathy.
- •Patients having received any of the following stem cell sources are eligible: G-CSF Mobilized
- •peripheral blood stem cells, G-CSF bone marrow, umbilical cord blood.
- •3. Male and female TAM patients = 2 years old at the time of first dose administration.
- •Patients < 12 years old can only be included in the study after first IA has shown that it is
- •safe and well tolerated in patients = 12 years old (Section 3.5).
- •4. The presence of TAM as per below diagnostic criteria at baseline (or screening if baseline visit is skipped). All the criteria have to be met for the patients included in the study: ? Elevated lactate dehydrogenase (any elevation above normal range)
- •? Thrombocytopenia with platelet count < 50x10e9/L or more than 50% decrease in
- •platelet count from the highest value achieved after transplant
- •? Anemia below lower limit of normal or anemia requiring transfusion support as per
- •center standard
- •? Schistocytes on peripheral blood smear (>2 per HPF) OR histologic evidence of
- •microangiopathy
- •? Absence of coagulopathy (no uncompensated disseminated intravascular coagulation, DIC) at screening
- •5. The presence of TAM high risk features at baseline (or screening if baseline visit is
- •skipped): Patients = 16 years must have a Lansky score of = 70 and patients > 16 must
- •have Karnofsky score = 70% and/or proteinuria (> 30 mg/dL) measured in two urine spot analyses.
- •6. Hypertension, defined for adults by SBP = 160 mmHg and/or DBP = 100 mmHg at baseline
- •(or screening if baseline visit is skipped), and for pediatric patients by blood pressure
- •greater than the 95th percentile for age, sex, and height (see Table 16-1). Additionally,
- •patients who were started on antihypertensive medication after HSCT or who have received additional antihypertensive medication after HSCT will be eligible, even if they don’t have elevated blood pressure
- •7. Able to receive antibiotic prophylaxis against N. meningitides for the
- •duration of the study.
- •8. Meningococcal vaccine(s) prior to LFG316 treatment if prior
- •vaccination cannot be confirmed. The choice of vaccine(s) should take
- •into account the serotypes prevalent in the geographic areas in which
- •study patients will be enrolled. In case vaccination is not possible or will
- •result in an unfavorable risk benefit ratio as judged by the investigator,
- •vaccination can
- •be postponed until deemed likely to be effective.
- •9. Patients <18 years old should receive vaccination for the prevention
- •of S. pneumoniae and H. influenzae type b prior to LFG316
- •administration. In case vaccination is not possible or will result in an
- •unfavorable risk benefit ratio as judged by the investigator, vaccination
- •can be postponed until deemed likely to be effective.
- •10. Weight of at least 10kg.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 10
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 30
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects fo
排除标准
- •1.Use of other investigational drugs at the time of enrollment, or within 5 half-lives of enrollment, or until the expected PD effect has returned to baseline, whichever is longer; or even longer if required by local regulations.
- •Concomitant investigational treatment, including treatment in the context of a clinical trial with marketed drugs (off-label) may be acceptable but requires approval by the sponsor on the case by case basis.
- •2. Known hypersensitivity to any constituent of the study medication.
- •3. Patients with steroid refractory graft versus host disease (SRGvHD). SRGvHD is defined as progression (=increase in overall grade) after 5 days on =2mg/kg methylprednisolone or equivalent OR no improvement
- •(no decrease in overall grade) after 10 days on = 2mg/kg methylprednisolone or equivalent. If patients are receiving steroids forGvHD prophylaxis as per center standard, progression after 5 days and no response after 10 days after doubling the steroid dose will be regarded as steroid refractory.
- •4. Patients with ALT > 10x ULN at screening.
- •5. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of
- •gestation, confirmed by a positive hCG laboratory test (at screening or baseline).
- •6. Women of child-bearing potential, defined as all women
- •physiologically capable of becoming pregnant, unless they are using
- •highly effective methods of contraception during dosing and for 45 days
- •after stopping study medication. Highly effective contraception methods
- •? Total abstinence (when this is in line with the preferred and usual
- •lifestyle of the subject. Periodic abstinence (i.e., calendar, ovulation,
- •symptothermal, postovulation methods) and withdrawal are not
- •acceptable methods of contraception.
- •? Female sterilization (have had surgical bilateral oophorectomy (with
- •or without hysterectomy), total hysterectomy or tubal ligation at least
- •six weeks before taking study treatment. In case of oophorectomy alone,
- •only when the reproductive status of the woman has been confirmed by
- •follow up hormone level assessment.
- •? Male sterilization (at least 6 m prior to screening). The vasectomized
- •male partner should be the sole partner for that subject.
- •? Use of oral, injected or implanted hormonal methods of contraception
- •or placement of an intrauterine device (IUD) or intrauterine system
- •(IUS) or other forms of hormonal contraception that have comparable
- •efficacy (failure rate <1%), for example hormone vaginal ring or
- •transdermal hormone contraception.
- •? In case of use of oral contraception women should have been stabile
- •on the same pill for a minimum of 3 months before taking study
- •7. Sexually active males unwilling to use a condom during intercourse
- •while taking drug and for 45 days after stopping investigational
- •medication. A condom is required to be used also by vasectomized men
- •in order to prevent delivery of the drug via seminal fluid. Male patients
- •should not father a child in this period.
- •8. Positive HIV (ELISA and Western blot) test result (checked at
- •screening). Historical local data will be acceptable if it the test was done
- •within one month before start of HSCT conditioning and not more than 3
- •months before study visit 3.
- •9. A positive Hepatitis B surface antigen or Hepatitis C test result at
- •screening. Historical local data will be acceptable if it the test was done
- •within one month before start of H
研究者
相似试验
进行中（未招募）
1 期
The study is to gather evidence of LFG316 efficacy intreatment of transplant associated microangiopathy (TAM) after hematopoetic precursor cell transplantation.Transplant associated microangiopathy (TAM)MedDRA version: 18.1Level: LLTClassification code 10050444Term: Microangiopathy NOSSystem Organ Class: 100000004866EUCTR2014-004972-49-FRovartis Pharma Services AG40
进行中（未招募）
1 期
The study is to gather evidence of LFG316 efficacy in treatment of transplant associated microangiopathy (TAM) after hematopoetic precursor cell transplantation.Transplant associated microangiopathy (TAM)MedDRA version: 20.0 Level: LLT Classification code 10050444 Term: Microangiopathy NOS System Organ Class: 100000023079EUCTR2014-004972-49-GBovartis Pharma Services AG7
已完成
不适用
Bioequivalence study of Olaparib Tablets 150 mgCTRI/2023/01/048868Cipla Limited44
已完成
不适用
Bioequivalence study of Vigabatrin Tablets 500 mg in refractory complex partial-seizure adult patients on Vigabatrin adjunctive therapy.CTRI/2020/11/029355Amneal Pharmaceuticals LLC36
已完成
不适用
Azathioprine Bioequivalence study in Rheumatoid ArthritisCTRI/2010/091/000070Orion Pharma42